Transurethral resection of superficial bladder cancer using 5-aminolevulinic acid: Are there any long-term benefits? Commentary

Nature Clinical Practice Urology

Volumn 3, Issue 5, 2006, Pages 254-255

  deVere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 aminolevulinic acid; Bladder cancer; Fluorescence; Recurrence; Transurethral resection

Indexed keywords

AMINOLEVULINIC ACID; MITOMYCIN C;

ABSENCE OF SIDE EFFECTS; BLADDER CANCER; BLADDER PAPILLOMA; BLUE LIGHT; CANCER RECURRENCE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; CYSTOSCOPY; DRUG COST; FLUORESCENCE ANALYSIS; FOLLOW UP; HOSPITAL COST; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHORT SURVEY; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; URINE CYTOLOGY; WHITE LIGHT;

EID: 33646679112     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro0455     Document Type: Short Survey

References (4)

1. Stapp E et al. (2000) Intravesical therapy and follow-up of superficial transitional cell carcinoma of the bladder. Int Braz J Urol 26: 242-249
2. Herr HW (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174: 2134-2137
3. Witjes JA et al. (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. Urology 52: 403-410
4. Grossman B Society of Urological Oncology, Winter Meeting 2005, Bethesda, MD (Podium presentation)